Adicet Bio, Inc. (ACET): Total Assets
$192.35M
As of 2025-12-31
$148.17M
As of 2026-06-30
-16.5%
3-year compound annual growth
+4.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $192.35M | -12.7% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $220.22M | +6.2% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $207.29M | -37.3% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $330.69M | -2.4% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $338.94M | +120.3% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $153.84M | +88.6% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $81.59M | n/c | 2021-03-12, Balance as of period end |
| 2018-12-31 | $109.94M | +99.2% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $55.19M | n/a | 2019-03-18, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $192.35M | -12.7% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $193.44M | +74.4% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $198.10M | -30.2% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $185.55M | +28.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $184.69M | +4.0% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $182.62M | +83.4% |
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $210.35M | -1.6% |
Compare ACET, TRVI, FHTX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗